Medicare Part D payments for neurologist-prescribed drugs.

about

Burden of neurological diseases in the US revealed by web searches Patient-reported financial barriers to adherence to treatment in neurology.Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.

P2860

Q33713117-58C46E95-885A-4DC8-8812-1E2DE8BF86ED Q37426903-53FEA10B-45D1-4BB5-BAD0-4D98C92ECDB0 Q47852975-C04A1C0C-0AB4-448F-87B0-5B5A35959E39

P2860

Medicare Part D payments for neurologist-prescribed drugs.

Item

http://www.wikidata.org/entity/Q36813242

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Medicare Part D payments for neurologist-prescribed drugs.

@ast

Medicare Part D payments for neurologist-prescribed drugs.

@en

type

Item

label

Medicare Part D payments for neurologist-prescribed drugs.

@ast

Medicare Part D payments for neurologist-prescribed drugs.

@en

prefLabel

Medicare Part D payments for neurologist-prescribed drugs.

@ast

Medicare Part D payments for neurologist-prescribed drugs.

@en

P1476

Medicare Part D payments for neurologist-prescribed drugs

@en

P2093

Brian C Callaghan

http://www.w3.org/2001/XMLSchema#string

James F Burke

http://www.w3.org/2001/XMLSchema#string

Kevin A Kerber

http://www.w3.org/2001/XMLSchema#string

Lesli E Skolarus

http://www.w3.org/2001/XMLSchema#string

P2860

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis

Physician awareness of drug cost: a systematic review

A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.

Impact of providing fee data on laboratory test ordering: a controlled clinical trial.

Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study.

A brief conceptual tutorial of multilevel analysis in social epidemiology: linking the statistical concept of clustering to the idea of contextual phenomenon.

The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?

What if the federal government negotiated pharmaceutical prices for seniors? An estimate of national savings.

How Medicare could get better prices on prescription drugs.

P304

1491-1498

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0000000000002589

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Lindsey B De Lott

Lindsey B DeLott

P577

2016-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27009256

http://www.w3.org/2001/XMLSchema#string

P932

4836880

http://www.w3.org/2001/XMLSchema#string

Medicare Part D payments for neurologist-prescribed drugs.

about

P2860

P2860

Medicare Part D payments for neurologist-prescribed drugs.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932